Investors

Explore how Hikma’s diversified portfolio, operational excellence, and global reach delivers value for investors

A proven track record of value creation

We are a multinational pharmaceutical company with a local presence across North America and Canada, MENA and Europe, providing our customers with a broad range of generic, specialty and branded pharmaceutical products

Hikma released its Interim Results on 7 August 2025 for the six months ended 30 June 2025.

Interim Results 2025

Recent results
Read about our progress

Annual Report

In 2024 we have continued to deliver on our mission to help shape a healthier world, and our leadership teams are advancing this agenda across our markets. We have been launching new products, signing partnerships, investing more into research and development, building new manufacturing plants, and deploying capital through acquisition to ensure we are well placed for continued growth.

Newsroom

Latest news

All news stories
Featured

Hikma announces CEO change and Board appointment

Press Release, Corporate